Investigational Drug Information for SGN-CD19A
What is the development status for investigational drug SGN-CD19A?
SGN-CD19A is an investigational drug.
There have been 4 clinical trials for SGN-CD19A.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Follicular, and Lymphoma, B-Cell. The leading clinical trial sponsors are Seagen Inc., Seattle Genetics, Inc., and [disabled in preview].
Summary for SGN-CD19A
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 904 |
| WIPO Patent Applications | 203 |
| Japanese Patent Applications | 98 |
| Clinical Trial Progress | Phase 1 (2016-08-01) |
| Vendors | 20 |
Recent Clinical Trials for SGN-CD19A
| Title | Sponsor | Phase |
|---|---|---|
| Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | Seagen Inc. | Phase 2 |
| Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | Seattle Genetics, Inc. | Phase 2 |
| Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | Seagen Inc. | Phase 2 |
Clinical Trial Summary for SGN-CD19A
Top disease conditions for SGN-CD19A
Top clinical trial sponsors for SGN-CD19A
US Patents for SGN-CD19A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
SGN-CD19A Development Update and Market Projection
SGN-CD19A is a discontinued Seattle Genetics antibody-drug conjugate directed at CD19-positive B-cell malignancies. Publicly available development records do not show ongoing clinical trials, FDA approval, commercial launch, Orange Book listing, or an active late-stage development program. The defensible base-case market projection is therefore zero commercial revenue unless a third party revives or licenses the program.
What is SGN-CD19A and what was it designed to treat?
SGN-CD19A was an investigational anti-CD19 antibody-drug conjugate developed by Seattle Genetics, now Seagen and part of Pfizer. The program targeted CD19, a B-cell surface antigen expressed across several non-Hodgkin lymphoma and leukemia subtypes.
The candidate was designed to deliver an auristatin-class cytotoxic payload to CD19-positive malignant B cells. Its development rationale was similar to other targeted ADC programs: antibody binding, internalization by the tumor cell, intracellular release of the cytotoxic payload, and cell death.
| Attribute | SGN-CD19A |
|---|---|
| Developer | Seattle Genetics, later Seagen |
| Modality | Antibody-drug conjugate |
| Target | CD19 |
| Intended diseases | B-cell non-Hodgkin lymphoma and related CD19-positive malignancies |
| Development status | Discontinued |
| FDA approval | None |
| Commercial status | Not marketed |
| Orange Book listing | None identified |
| Public revenue | None |
| Biosimilar relevance | None; SGN-CD19A is not an approved biologic |
Public disclosures described SGN-CD19A as a clinical-stage program rather than a registrational asset. The program did not produce a marketed product or a public Phase 3 development plan.
What is the current development status of SGN-CD19A?
SGN-CD19A is no longer an active clinical development program in the publicly disclosed Seattle Genetics or Seagen pipeline.
The program reached early clinical testing in patients with B-cell malignancies. Public clinical disclosures focused on safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The candidate did not advance into a confirmatory registration program.
Development timeline
| Period | Development event |
|---|---|
| Early 2010s | Seattle Genetics advances SGN-CD19A into clinical development |
| 2013-2015 | Early clinical evaluation in B-cell malignancies |
| 2015-2016 | Program receives limited public pipeline visibility |
| After 2016 | SGN-CD19A disappears from active late-stage corporate development disclosures |
| 2023 | Pfizer completes acquisition of Seagen |
| Current status | No public evidence of active trials, regulatory review, approval, or commercial development |
The key commercial conclusion is that SGN-CD19A has not progressed from an exploratory or early clinical asset into a registration-stage product. Its discontinuation removes the normal launch pathway used for valuation of an active oncology candidate.
Why was SGN-CD19A discontinued?
The public record does not identify a single definitive reason for discontinuation. The available evidence supports a combination of development and competitive factors rather than a publicly documented regulatory rejection.
Likely program-level constraints included:
- Early-stage efficacy that did not justify expansion into registrational trials.
- Safety and tolerability considerations associated with auristatin ADCs.
- Competition from more advanced CD19-directed treatments.
- Rapid changes in B-cell malignancy treatment, including CAR-T therapies, bispecific antibodies, naked antibodies, and other ADCs.
- Portfolio prioritization by Seattle Genetics around higher-value assets.
SGN-CD19A competed for development resources against Seattle Genetics programs with stronger commercial or clinical positioning, including brentuximab vedotin and later-stage ADC and immuno-oncology candidates.
No public FDA Complete Response Letter, clinical hold announcement, or litigation record indicates that a specific regulatory action ended the program. The more supportable interpretation is portfolio discontinuation after early-stage development.
What FDA regulatory status does SGN-CD19A have?
SGN-CD19A has no FDA approval, biologics license application, approved label, or public exclusivity period.
| FDA-related category | Status |
|---|---|
| Investigational status | Early clinical development |
| FDA approval | None |
| Biologics License Application | No public approval record |
| New Drug Application | Not applicable to the unapproved ADC |
| Breakthrough Therapy designation | No public designation identified |
| Fast Track designation | No public designation identified |
| Priority Review | None |
| FDA exclusivity | None |
| Orange Book listing | None |
| Purple Book listing | None |
Because SGN-CD19A was never approved, it does not have regulatory exclusivity under the Hatch-Waxman framework or the Biologics Price Competition and Innovation Act. It also has no approved reference product status for biosimilar development.
What patents protect SGN-CD19A?
No complete, publicly verified patent estate can be assigned to SGN-CD19A from the available product disclosures alone.
An ADC program may be protected through several patent categories:
- Anti-CD19 antibody sequences and binding domains.
- Antibody-drug conjugate compositions.
- Linker-payload chemistry.
- Drug-to-antibody ratio and conjugation methods.
- Pharmaceutical formulations.
- Treatment methods for CD19-positive cancers.
- Manufacturing and purification processes.
Seattle Genetics held broad ADC platform patents and product-specific patent families. However, platform ownership does not establish that every patent covers SGN-CD19A specifically. The candidate’s unapproved status also means there is no FDA Orange Book patent list identifying patents that would trigger a Paragraph IV certification.
Patent and exclusivity assessment
| Issue | SGN-CD19A assessment |
|---|---|
| Product-specific Orange Book patents | None |
| FDA-listed formulation patents | None |
| Method-of-use patents tied to an approved label | None |
| Patent-term extension | None |
| Pediatric exclusivity | None |
| Biosimilar exclusivity | None |
| Patent litigation over an approved product | No public case identified |
| Freedom-to-operate risk | Potentially relevant only if the program is revived |
If a company attempted to revive SGN-CD19A, it would need to review surviving composition, antibody, linker-payload, manufacturing, and use patents. The practical issue would be enforceability and remaining patent term, not Orange Book litigation.
What patent litigation or Paragraph IV challenges affect SGN-CD19A?
No public Paragraph IV challenge affects SGN-CD19A because the candidate has no FDA-approved reference product and no Orange Book listing.
There is also no identified patent litigation concerning a generic or biosimilar version of SGN-CD19A. Any disputes involving related CD19 antibodies or ADC platform technology would need to be analyzed separately and would not automatically apply to this candidate.
The absence of an Orange Book listing means:
- No abbreviated new drug application is tied to SGN-CD19A.
- No statutory Paragraph IV notice process applies.
- No 30-month stay is available under the Hatch-Waxman framework.
- No approved-product patent expiry date determines generic entry.
What is the competitive landscape for CD19-directed therapies?
SGN-CD19A entered a therapeutic area that became substantially more competitive after its early development period.
| Product or modality | Target or mechanism | Commercial position |
|---|---|---|
| Rituximab | CD20 monoclonal antibody | Established B-cell malignancy therapy |
| Tafasitamab | CD19 monoclonal antibody | Approved for selected relapsed or refractory large B-cell lymphoma use |
| Blinatumomab | CD19-directed CD3 bispecific | Established acute lymphoblastic leukemia product |
| Brexucabtagene autoleucel | CD19 CAR-T | Approved for selected B-cell malignancies |
| Lisocabtagene maraleucel | CD19 CAR-T | Approved for selected large B-cell lymphoma settings |
| Loncastuximab tesirine | CD19 ADC | Approved for relapsed or refractory large B-cell lymphoma |
| Polatuzumab vedotin | CD79b ADC | Approved in diffuse large B-cell lymphoma combinations |
| SGN-CD19A | CD19 ADC | Discontinued, no commercial product |
Loncastuximab tesirine is the most direct commercial comparator because it is also a CD19-directed ADC. Its approval established that CD19 ADCs can reach the market, but it also raised the competitive bar for efficacy, safety, dosing, and differentiation.
SGN-CD19A would have needed a clear advantage in response durability, safety, outpatient convenience, combination use, or treatment sequencing. Public development records do not show that it achieved such differentiation.
How does SGN-CD19A compare with loncastuximab tesirine?
| Factor | SGN-CD19A | Loncastuximab tesirine |
|---|---|---|
| Developer | Seattle Genetics | ADC Therapeutics |
| Target | CD19 | CD19 |
| Modality | ADC | ADC |
| Clinical outcome | Development discontinued | FDA approved |
| Commercial product | None | Zynlonta |
| Regulatory pathway | No application resulting in approval | Approved under FDA pathway |
| Patent and exclusivity framework | No Orange Book product estate | Approved-product patent and regulatory framework |
| Market opportunity | No current opportunity | Relapsed or refractory B-cell lymphoma market |
| Competitive position | Pre-commercial | Commercial but competitive |
The comparison demonstrates the execution gap between an early clinical ADC and an approved CD19 product. SGN-CD19A did not create a commercial foothold before the CD19 treatment market matured.
What market projection is appropriate for SGN-CD19A?
The base-case market projection is zero revenue because SGN-CD19A is not approved, is not marketed, and has no public evidence of active development.
Scenario analysis
| Scenario | Probability implication | Commercial outcome |
|---|---|---|
| Base case: continued discontinuation | Highest support from public record | $0 revenue |
| Asset revival by Seagen/Pfizer | Low | Requires new clinical and regulatory investment |
| Licensing to another company | Low | Requires transfer of rights and renewed clinical validation |
| Platform or technology reuse | Possible in principle | Value may reside in components, not SGN-CD19A as a product |
| Direct commercial launch | Not supportable from current status | No near-term launch |
A quantitative peak-sales estimate would not be reliable. The program has no active pivotal trial, no FDA filing, no approved indication, no launch date, and no disclosed pricing or access strategy.
If revived, the addressable market would be limited by:
- Competition from CD19 CAR-T products.
- Bispecific antibody adoption.
- Existing CD19 ADC treatment.
- CD20-directed therapies.
- Treatment-line restrictions.
- Safety and sequencing concerns.
- Physician preference for established products.
- Manufacturing complexity associated with ADCs.
Any renewed development would likely require a new clinical strategy rather than a simple continuation of the original program.
What revenue exposure does SGN-CD19A create for Pfizer or Seagen?
SGN-CD19A does not create material current revenue exposure for Pfizer or Seagen. It is not included in the commercial product base and does not affect current reported sales in the manner of approved products such as Adcetris.
Its financial relevance is limited to:
- Potentially stranded research and development expenditure.
- The opportunity cost of discontinued development.
- Possible residual value in antibody, payload, linker, or conjugation technology.
- Any surviving intellectual property that can support other programs.
The Pfizer acquisition of Seagen does not by itself reactivate SGN-CD19A. Acquisition ownership is different from a disclosed development decision, clinical restart, licensing transaction, or regulatory filing.
What generic and biosimilar entry risks exist?
There is no direct generic or biosimilar entry risk because SGN-CD19A has no approved product.
A revived program could face indirect competition from:
- Biosimilars to established anti-CD20 products.
- New CD19 bispecific antibodies.
- Next-generation CAR-T therapies.
- Other CD19 ADCs.
- Off-the-shelf cellular therapies.
- Low-cost antibody combinations.
The principal risk would be clinical substitution rather than statutory generic entry. A new SGN-CD19A development program would need to demonstrate value against therapies that already have commercial, regulatory, and clinical infrastructure.
Key Takeaways
- SGN-CD19A was an investigational CD19-directed ADC developed by Seattle Genetics.
- The program reached early clinical testing in B-cell malignancies but did not advance to a registration-stage program.
- No public evidence shows active trials, FDA approval, commercial launch, Orange Book listing, or regulatory exclusivity.
- No Paragraph IV challenge, generic litigation, or biosimilar litigation applies.
- A complete product-specific patent estate cannot be verified from public product disclosures alone.
- The base-case market projection is $0.
- Any future value would depend on revival, licensing, or reuse of underlying ADC technology.
- Loncastuximab tesirine is the closest commercial comparator and illustrates the competitive hurdle SGN-CD19A would face.
FAQs About SGN-CD19A
Is SGN-CD19A the same drug as loncastuximab tesirine?
No. SGN-CD19A and loncastuximab tesirine are separate CD19-directed ADC programs developed by different companies.
Can SGN-CD19A still be approved in the future?
Only through a renewed development program, additional clinical evidence, and FDA review. No public restart is identified.
Does SGN-CD19A have a biosimilar competitor?
No. It was never approved and therefore has no reference-product status for biosimilar competition.
Was SGN-CD19A included in the Seagen acquisition pipeline?
Seagen was acquired by Pfizer, but acquisition ownership does not indicate that SGN-CD19A remained an active development asset. Public disclosures do not show a current clinical program for the candidate.
What would determine the value of a license to SGN-CD19A?
The principal factors would be surviving patent term, antibody and payload ownership, freedom to operate, archived clinical data, manufacturing feasibility, and whether the candidate can differentiate itself from approved CD19 therapies.
References
-
ClinicalTrials.gov. (n.d.). Clinical studies involving SGN-CD19A. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
Pfizer Inc. (2023). Pfizer completes acquisition of Seagen. https://www.pfizer.com/
-
Seagen Inc. (2015-2022). Annual reports and securities filings. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/searchedgar/companysearch.html
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book. https://www.fda.gov/
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2023). Zynlonta (loncastuximab tesirine-lpyl) prescribing information. https://www.accessdata.fda.gov/```
More… ↓
